Ocera Therapeutics, Inc. Therapeutics To Present At 13th Annual Biotechnology Industry Organization (BIO) Investor Forum
PALO ALTO, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the 13th Annual BIO Investor Forum being held at the Palace Hotel in San Francisco, California. Ocera's presentation is scheduled for Tuesday, October 7, 2014 at 3:00 PM PT in the Presidio conference room.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 30 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
